Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Emtansine vs Trastuzumab + Docetaxel in First-Line HER2+ Metastatic Breast Cancer
NCT00679341Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2008
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab emtansine in HER2-positive breast cancer, sponsored by Roche. Started Sep 2008; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00679341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00679341.